...a 2006 deal under which Thallion licensed TLN-232 (CAP-232) from ExperGen. The court also ordered ExperGen...
...to reimburse Thallion for a portion of legal expenses. In 2010, the court ruled that ExperGen...
...caused to ExperGen, but said that it would decide on damages in future court proceedings. ExperGen...

...Thallion said the International Chamber of Commerce International Court of Arbitration ruled in favor of ExperGen...
...dispute between the companies over a 2006 deal in which Thallion licensed TLN-232 (CAP-232) from ExperGen...
...kinase M2 isozyme (PKM2) was being evaluated in metastatic melanoma (see BioCentury, July 13, 2009). ExperGen Drug Development GmbH...

...dispute with ExperGen over TLN-232 (CAP-232), which Thallion (formerly Caprion Pharmaceuticals Inc. ) licensed from ExperGen...
...over TLN-232 (CAP-232), which Thallion (formerly Caprion Pharmaceuticals Inc. ) licensed from ExperGen in 2006. ExperGen...
...another dispute over license fees for the heptapeptide targeting pyruvate kinase M2 isozyme (PKM2) . ExperGen...

...to enroll up to 49 patients due to an ongoing dispute with ExperGen Drug Development GmbH (Vienna, Austria). ExperGen...
...will re-evaluate the status of its TLN-232 program based on the outcome of the adjudication. ExperGen...

...to grant Orphan Drug designation for ExperGen's miltefosine to treat cutaneous T cell lymphoma (CTCL). ExperGen Drug Development GmbH...

...Inc. (now Thallion) licensed from Expergen in 2006 (see BioCentury, March 20, 2006). Thallion said Expergen...
...Thallion did not pay a US$200,000 license fee on time. Thallion disputed that claim, which Expergen...
...on Thallion’s close of C$0.37 on Jan. 16, the day before the deal was announced. Expergen...

...overcome that limitation. CAP-232 (formerly TT-232 ) was in-licensed from Biostatin via technology transfer company ExperGen Drug Development GmbH...

...Caprion in-licensed CAP-232 ( TT-232 ) from technology transfer company Expergen for an undisclosed amount of...
...melanoma and pancreatic cancer in the fourth quarter. Expergen is eligible for milestones and royalties. Expergen...
...will receive an undisclosed payment in stock and cash. Caprion Pharmaceuticals Inc. , Montreal, Quebec Expergen...

...Caprion (Montreal, Quebec) in-licensed CAP-232 ( TT-232 ) from technology transfer company Expergen (Vienna, Austria) for...
...melanoma and pancreatic cancer in the fourth quarter. Expergen is eligible for milestones and royalties. Expergen...